Low-Income Group Psilocybin Assisted Therapy for Depression (LIGPATD)

This open-label feasibility study (n=24) will investigate the potential of group psilocybin-assisted therapy for depression in low-income adults in Oregon.

The study aims to assess recruitment, retention, acceptability, and safety of the treatment model. Participants, aged 21 or older, with a DSM-5 diagnosis of Major Depression Disorder and income at or below 200% of the Federal Poverty Line, will undergo two group preparation sessions, two psilocybin sessions, and two group integration sessions.

Led by Matthew Hicks from the National University of Natural Medicine, the study will follow the Oregon Psilocybin Services (OPS) rules, with participants placed in cohorts of five to six.

The primary outcome measures include recruitment and retention feasibility, acceptability, and preliminary safety and tolerability of the therapy. Additional measures, such as the PROMIS-29 and Altered State of Consciousness rating scale, will also be assessed.

Recruitment is expected to begin in August 2024, with completion anticipated by October 2024. The study will provide valuable insights into the potential of psilocybin-assisted group therapy for depression in low-income populations.

Topic Depression Safety
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.